Short Interest in Pulse Biosciences, Inc. (NASDAQ:PLSE) Drops By 14.4%

Pulse Biosciences, Inc. (NASDAQ:PLSE) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 2,430,000 shares, a drop of 14.4% from the May 31st total of 2,840,000 shares. Currently, 14.9% of the company’s shares are sold short. Based on an average trading volume of 220,500 shares, the short-interest ratio is presently 11.0 days.

Pulse Biosciences Stock Performance

NASDAQ:PLSE traded down $0.36 during mid-day trading on Monday, hitting $10.83. The company had a trading volume of 168,506 shares, compared to its average volume of 205,706. Pulse Biosciences has a fifty-two week low of $3.78 and a fifty-two week high of $14.96. The business’s fifty day moving average is $10.14 and its two-hundred day moving average is $9.56. The firm has a market cap of $598.03 million, a P/E ratio of -13.37 and a beta of 1.75.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Insider Activity at Pulse Biosciences

In related news, CEO Burke Thomas Barrett bought 10,000 shares of the business’s stock in a transaction on Monday, May 20th. The shares were purchased at an average price of $8.56 per share, with a total value of $85,600.00. Following the completion of the purchase, the chief executive officer now owns 10,000 shares of the company’s stock, valued at approximately $85,600. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 71.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences during the first quarter worth about $88,000. Cetera Advisors LLC acquired a new stake in shares of Pulse Biosciences during the first quarter worth about $109,000. PNC Financial Services Group Inc. acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth about $242,000. Finally, Inspire Investing LLC raised its position in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after purchasing an additional 10,039 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research note on Thursday.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.